After being treated with different samples (PBS, TLND, Ang-PMSe/TLND, Ang-PAMSe and Ang-PAMSe/TLND), there was no difference in the proportion of M1-type macrophages (CD11b+CD86+) in GBM tissues of mice treated with TLND and Ang-PMSe/TLND groups compared with the PBS group (Fig. 7e, f and Supplementary Figs. 53 and 54), while Ang-PAMSe and Ang-PAMSe/TLND treatment groups increased to 10.6% and 13.4%, which were approximately 3.6 and 4.5 times higher than those in the PBS group. The gene discussed is CD86; the disease is glioblastoma.